Segment Information and Concentration of Business Risk (Tables)

6 Months Ended

Jun. 30, 2015

Segment Information and Concentration of Business Risk [Abstract]

Segment information

The following is our segment information for the three and six months ended June 30, 2015 (in thousands).

Three Months Ended June 30, 2015	Isis Core			Akcea Therapeutics				Total
Revenue:
Research and development		$	119,658		$	—			$	119,658
Licensing and royalty			770			—				770
Total segment revenue		$	120,428		$	—			$	120,428
Income (loss) from operations		$	53,588		$	(8,942	)		$	44,646

Six Months Ended June 30, 2015	Isis Core			Akcea Therapeutics				Total
Revenue:
Research and development		$	181,551		$	—			$	181,551
Licensing and royalty			1,461			—				1,461
Total segment revenue		$	183,012		$	—			$	183,012
Income (loss) from operations		$	51,357		$	(16,040	)		$	35,317

The following is our segment information for the three and six months ended June 30, 2014 (in thousands) revised for comparative purposes to show operating costs for Akcea-related projects in 2014:

Three Months Ended June 30, 2014	Isis Core				Akcea Therapeutics				Total
Revenue:
Research and development		$	56,628			$	—			$	56,628
Licensing and royalty			448				—				448
Total segment revenue		$	57,076			$	—			$	57,076
Loss from operations		$	(1,042	)		$	(5,608	)		$	(6,650	)

Six Months Ended June 30, 2014	Isis Core				Akcea Therapeutics				Total
Revenue:
Research and development		$	76,177			$	—			$	76,177
Licensing and royalty			9,060				—				9,060
Total segment revenue		$	85,237			$	—			$	85,237
Loss from operations		$	(26,653	)		$	(9,664	)		$	(36,317	)

Revenue from significant partners

We have historically funded our operations from collaborations with corporate partners and a relatively small number of partners have accounted for a significant percentage of our revenue. Revenue from significant partners, which is defined as ten percent or more of our total revenue, was as follows:

	Three Months Ended June 30,				Six Months Ended  June 30,
	2015		2014		2015		2014
Partner A		76 %		0 %		50 %		0 %
Partner B		15 %		60 %		31 %		52 %
Partner C		4 %		6 %		11 %		8 %
Partner D		1 %		27 %		1 %		22 %